Compare Stocks: BBOT, NRIX, VRDN, and PGEN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$9.15 -1.2%	$8.55	$7.00 ▼ $14.87	$733.48M	0.36	354,064 shs	58,130 shs
NRIX Nurix Therapeutics	$27.24 +2.0%	$24.01	$8.19 ▼ $28.23	$2.80B	1.79	1.46 million shs	317,817 shs
PGEN Precigen	$7.36 -0.9%	$5.96	$2.99 ▼ $7.72	$2.62B	1.02	4.69 million shs	1.62 million shs
VRDN Viridian Therapeutics	$24.06 -0.8%	$20.29	$13.18 ▼ $34.29	$2.72B	0.91	2.16 million shs	205,456 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	-1.17%	-3.54%	+5.83%	+4.75%	+925,999,900.00%
NRIX Nurix Therapeutics	-0.89%	-3.89%	+14.00%	+51.16%	+180.27%
PGEN Precigen	+1.92%	+3.63%	+36.90%	+64.52%	+74.18%
VRDN Viridian Therapeutics	+0.33%	-2.18%	+23.15%	+39.03%	+30.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBOT BridgeBio Oncology Therapeutics	$9.15 -1.2%	$8.55	$7.00 ▼ $14.87	$733.48M	0.36	354,064 shs	58,130 shs
NRIX Nurix Therapeutics	$27.24 +2.0%	$24.01	$8.19 ▼ $28.23	$2.80B	1.79	1.46 million shs	317,817 shs
PGEN Precigen	$7.36 -0.9%	$5.96	$2.99 ▼ $7.72	$2.62B	1.02	4.69 million shs	1.62 million shs
VRDN Viridian Therapeutics	$24.06 -0.8%	$20.29	$13.18 ▼ $34.29	$2.72B	0.91	2.16 million shs	205,456 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBOT BridgeBio Oncology Therapeutics	-1.17%	-3.54%	+5.83%	+4.75%	+925,999,900.00%
NRIX Nurix Therapeutics	-0.89%	-3.89%	+14.00%	+51.16%	+180.27%
PGEN Precigen	+1.92%	+3.63%	+36.90%	+64.52%	+74.18%
VRDN Viridian Therapeutics	+0.33%	-2.18%	+23.15%	+39.03%	+30.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBOT BridgeBio Oncology Therapeutics	2.75	Moderate Buy	$24.40	166.67% Upside
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.21	25.61% Upside
PGEN Precigen	2.80	Moderate Buy	$14.50	97.14% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.54	60.16% Upside

Current Analyst Ratings Breakdown

Latest BBOT, NRIX, VRDN, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	BBOT BridgeBio Oncology Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$27.00 ➝ $25.00
8/10/2026	NRIX Nurix Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$33.00 ➝ $36.00
8/7/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $36.00
8/7/2026	VRDN Viridian Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
8/5/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$14.00 ➝ $18.00
8/5/2026	PGEN Precigen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
8/3/2026	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
7/28/2026	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$36.00 ➝ $38.00
7/22/2026	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $31.00
7/17/2026	NRIX Nurix Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	$4.03 per share	N/A
NRIX Nurix Therapeutics	$36.77M	76.89	N/A	N/A	$5.29 per share	5.15
PGEN Precigen	$9.68M	270.88	N/A	N/A	$0.12 per share	61.29
VRDN Viridian Therapeutics	$71.13M	38.33	N/A	N/A	$4.98 per share	4.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBOT BridgeBio Oncology Therapeutics	-$134.04M	-$2.76	N/A	N/A	N/A	N/A	-46.90%	-42.17%	N/A
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	8.55	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest BBOT, NRIX, VRDN, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	BBOT BridgeBio Oncology Therapeutics	N/A	-$705.20	N/A	-$705.20	N/A	N/A
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBOT BridgeBio Oncology Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBOT BridgeBio Oncology Therapeutics	N/A	4.69	4.69
NRIX Nurix Therapeutics	N/A	6.34	6.34
PGEN Precigen	2.15	4.58	3.89
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBOT BridgeBio Oncology Therapeutics	54.89%
NRIX Nurix Therapeutics	N/A
PGEN Precigen	33.51%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BBOT BridgeBio Oncology Therapeutics	24.40%
NRIX Nurix Therapeutics	6.70%
PGEN Precigen	41.40%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBOT BridgeBio Oncology Therapeutics	N/A	80.17 million	60.61 million	N/A
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable
PGEN Precigen	190	356.51 million	208.92 million	Optionable
VRDN Viridian Therapeutics	50	113.29 million	110.57 million	Optionable

BBOT, NRIX, VRDN, and PGEN Headlines

Recent News About These Companies

Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN

August 27 at 3:20 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26 at 7:31 PM | theglobeandmail.com

Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

August 26 at 4:24 AM | marketbeat.com

Parkman Healthcare Partners LLC Makes New $25.31 Million Investment in Viridian Therapeutics, Inc. $VRDN

August 25 at 6:40 AM | marketbeat.com

Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

August 24 at 3:51 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

August 21, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares

August 20, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN

August 20, 2026 | marketbeat.com

GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN

August 19, 2026 | marketbeat.com

93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.

August 18, 2026 | marketbeat.com

1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC

August 18, 2026 | marketbeat.com

Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN

August 18, 2026 | marketbeat.com

Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $38.93

August 16, 2026 | americanbankingnews.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 11, 2026 | marketbeat.com

HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

August 10, 2026 | marketbeat.com

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

August 8, 2026 | theglobeandmail.com

Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says

August 8, 2026 | finance.yahoo.com

Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN

August 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT, NRIX, VRDN, and PGEN Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$9.15 -0.11 (-1.19%)

As of 12:57 PM Eastern

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

Nurix Therapeutics NASDAQ:NRIX

$27.24 +0.53 (+1.98%)

As of 12:57 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Precigen NASDAQ:PGEN

$7.36 -0.07 (-0.88%)

As of 12:58 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Viridian Therapeutics NASDAQ:VRDN

$24.06 -0.20 (-0.82%)

As of 12:58 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBOT, NRIX, VRDN, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBOT, NRIX, VRDN, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBOT, NRIX, VRDN, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT, NRIX, VRDN, and PGEN Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Nurix Therapeutics NASDAQ:NRIX

Precigen NASDAQ:PGEN

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBOT, NRIX, VRDN, and PGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBOT, NRIX, VRDN, and PGEN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBOT, NRIX, VRDN, and PGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT, NRIX, VRDN, and PGEN Company Descriptions

BridgeBio Oncology Therapeutics NASDAQ:BBOT

Nurix Therapeutics NASDAQ:NRIX

Precigen NASDAQ:PGEN

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools